a high-tech pharmaceutical enterprise integrated of R&D, production and sales.
Hwasun Pharmaceutical Co. Ltd., founded in 2005, is a high-tech pharmaceutical enterprise integrating of R&D, manufacture and sales. The company is located in the suburb of southern city Guilin and covers a floor area of 111.64 Acre.
Hwasun owns 4 workshops and eight production lines for API and preparation, with an annual manufacture capacity of 500 million tablets (pellets) for solid preparation, 15 million pieces of external preparation ointment (cream) and 150 tons of API. Manufacturing licenses are granted for 20 products including APIs, tablets, capsules, granules, external cream (ointment) and other dosage forms. After long term unremitting self-development and technology introduction, Hwasun has possessed advanced pharmaceutical raw materials and preparation production technology, especially in the research, production and sales of proton pump inhibitor series, pellets and sustained-release preparations. With CEP acquisition of main prodouct Lansoprazole in 2014, Hwasun becomes one of the few manufacturers to obtain this certification in China.
Hwasun has been granted various govern rewards as a national-level high-tech pharmaceutical enterprise in technological innovation and best enterprises,etc.
The company has passed the intellectual property management system certification, and has 7 invention patents, 5 utility model patents, 5 design patents, and 7 registered and usable trademarks such as "Renkang" and "Valxin".
Hwasun operates the enterprise strictly in accordance with international, national, and industrial laws and regulations, implements the management idea of combining humanization and system standardization, abides the business philosophy of "unity and cooperation, emphasis on efficiency, pioneering and enterprising, and pursuit of excellence", and Regards talents as the most important resource and employees as the most valuable wealth and strategic partners of company. In product positioning, we insist on independent development and foreign introduction simultaneously, and most of the varieties we choose are advanced dosage forms with high technical content and unique varieties with market potential. In product sales, we insist on occupying the market with product technology advantages and high quality. Our API products have been distributed to many renowned Chinese and overseas customers. With regard to formulation products, Valsartan Dispersible Tablets (brand name ” Xie Xin”) and Gliclazide Sustained Released Capsules (brand name ” Xie Erping”) have gain great market share and reputation in China, with good quality and clinical efficacy. The outstanding sales performance is over 20% annual growth in recent year.
To become an outstanding pharmaceutical company is Hwasun's goal. Technology research and development is the guideline of development direction in future. The development of pellets, sustained-release preparations and continuous development of top, innovative and cutting-edge pharmaceutical products are our focus. To meet the needs of the global market and provide high-quality and innovative pharmaceutical products is our mission. Hwasun will try its best to make perfect in the human health and revitalize China's pharmaceutical industry with other professionals.